Medicines under the Biocase and Allandiol brands sold online do not have health registration, according to the agency
The (National Health Surveillance Agency) the marketing and dissemination of cannabis-based medicines under the brands Biocase and Allandiol. The resolution was published in DOU (Official Gazette of the Union), on Monday (May 11, 2026). Read (PDF – 188 KB).
The measure affects the cannabis-derived products Allandiol Forte Black 1:1 and Allandiol Full Spectrum 300 mg, manufactured by .
According to the regulatory agency, the medicines do not have health registration and the company responsible does not have an AFE (Operating Authorization) to manufacture or market them.
The irregularities were found on the company’s website and profile on Instagram, where products were offered and supposed therapeutic benefits were advertised without health approval.
The measure also applies to any person or company that advertises, sells or publicizes these products, due to the risk to public health.
Anvisa said it had suspended the marketing, distribution and use of the drug Kefazol – 1 g powder for injectable solution (CT FA VD Trans x 10 ml) after the company announced the voluntary recall of batches 111626C, 111750C and 112056C. The action was motivated by quality deviation, related to a failure in the packaging process, according to the agency.
In a note sent to the portal, the Alma Viva Institute said it had received the publication of the resolution “with surprise” and stated that there was “evident confusion between different companies belonging to the same business group”.
The institution declared that it was “a regular center for teaching, research and assistance in mental health” and that “does not sell medicines”.
